Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Inflammatory Bowel Diseases

  Free Subscription


25.11.2024

2 Aliment Pharmacol Ther
2 BMC Gastroenterol
1 Clin Res Hepatol Gastroenterol
1 Dig Dis
2 Dig Dis Sci
1 Gastroenterol Hepatol
4 Gastroenterology
4 J Crohns Colitis
2 Lancet Gastroenterol Hepatol
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. PAPAMICHAEL K, Cheifetz AS
    Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
    Aliment Pharmacol Ther. 2024 Nov 19. doi: 10.1111/apt.18360.
    PubMed        

  2. HONG SN, Song JH, Kim SJ, Park YH, et al
    Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease.
    Aliment Pharmacol Ther. 2024 Nov 18. doi: 10.1111/apt.18354.
    PubMed         Abstract available


    BMC Gastroenterol

  3. FANG Z, Qu S, Ji X, Zheng C, et al
    Correlation between PDGF-BB and M1-type macrophage in inflammatory bowel disease: a case-control study.
    BMC Gastroenterol. 2024;24:417.
    PubMed         Abstract available

  4. CHEN X, Zhou Q, Wang B, Feng D, et al
    Efficacy and safety of tanshinone IIA in combination with mesalazine in the treatment of ulcerative colitis: a Systematic review and meta-analysis.
    BMC Gastroenterol. 2024;24:410.
    PubMed         Abstract available


    Clin Res Hepatol Gastroenterol

  5. SOUAID C, Fares E, Primard P, Macaigne G, et al
    A Review Investigating delays in Crohn's disease diagnosis.
    Clin Res Hepatol Gastroenterol. 2024 Nov 15:102500.
    PubMed         Abstract available


    Dig Dis

  6. ZHANG Q, Lou D, Zhang Y, Xu A, et al
    A Meta-Analysis of Proton Pump Inhibitor Exposure and the Risk of Adverse Outcomes in Patients with Inflammatory Bowel Disease.
    Dig Dis. 2024 Nov 21:1-16. doi: 10.1159/000542729.
    PubMed         Abstract available


    Dig Dis Sci

  7. YOUN J, Hsia K, Khadilkar S, Zeina T, et al
    The Impact of Obesity on the Prevalence and Complications of Perianal Fistulas of Crohn's Disease.
    Dig Dis Sci. 2024 Nov 16. doi: 10.1007/s10620-024-08729.
    PubMed         Abstract available

  8. SHEEHAN JL, Jordan AA, Newman KL, Johnson LA, et al
    Disparities in Vaccination Amongst Socially Vulnerable Patients with Inflammatory Bowel Disease.
    Dig Dis Sci. 2024 Nov 15. doi: 10.1007/s10620-024-08733.
    PubMed         Abstract available


    Gastroenterol Hepatol

  9. OLIVERA PA, Balderramo DC, Lasa JS, Zubiaurre I, et al
    Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe inflammatory bowel disease in Argentina: Data from the RISE-AR study.
    Gastroenterol Hepatol. 2024 Nov 14:502287. doi: 10.1016/j.gastrohep.2024.502287.
    PubMed         Abstract available


    Gastroenterology

  10. ZHAO Q, Duck LW, Killian JT Jr, Rosenberg AF, et al
    Crohn's Patients and Healthy Infants Share Immunodominant B Cell Response to Commensal Flagellin Peptide Epitopes.
    Gastroenterology. 2024;167:1415-1428.
    PubMed         Abstract available

  11. AGRAWAL M, Ungaro RC, Rajauria P, Magee J, et al
    High serum pesticide levels are associated with increased odds of inflammatory bowel disease in a nested case-control study.
    Gastroenterology. 2024 Nov 9:S0016-5085(24)05692.
    PubMed        

  12. DI VINCENZO F, Quintero MA, Mendygral P, Abreu MT, et al
    Gender Inequity in Pharma-Supported Inflammatory Bowel Disease Presentations: Shining a Light on Opportunities for Equality and Transparency in Medical Research.
    Gastroenterology. 2024;167:1256-1259.
    PubMed        

  13. SINGH S, Loftus EV Jr, Limketkai BN, Haydek JP, et al
    AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.
    Gastroenterology. 2024;167:1307-1343.
    PubMed         Abstract available


    J Crohns Colitis

  14. MANCHERON A, Dumas A, Nion Larmurier I, Landman C, et al
    Development and Validation of a Sexual Quality of Life Score for Youths with Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Nov 22:jjae175. doi: 10.1093.
    PubMed         Abstract available

  15. DE-LA-CRUZ JL, Gomollon F, Louro J, Lopez Perez J, et al
    Impact Of Hladqa1*05 And Hladqa1*03 On Safety And Loss Of Response To Anti-Tnf In Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Nov 21:jjae178. doi: 10.1093.
    PubMed         Abstract available

  16. JATKOWSKA A, White B, Gkikas K, Seenan JP, et al
    Partial Enteral Nutrition in the Management of Crohn's Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2024 Nov 20:jjae177. doi: 10.1093.
    PubMed         Abstract available

  17. ATTAUABI M, Madsen GR, Bendtsen F, Seidelin JB, et al
    Incidence, disease burden and clinical presentation of patients newly diagnosed with inflammatory bowel disease in a population-based inception cohort.
    J Crohns Colitis. 2024 Nov 20:jjae176. doi: 10.1093.
    PubMed         Abstract available


    Lancet Gastroenterol Hepatol

  18. D'HAENS G, Taxonera C, Lopez-Sanroman A, Nos P, et al
    Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00317.
    PubMed         Abstract available

  19. MULLIGAN RJ, Lamb CA
    Vedolizumab prophylaxis against postoperative Crohn's disease recurrence.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00352.
    PubMed        


    PLoS One

  20. SEO SM, Kim NW, Yoo ES, Lee JH, et al
    Development of a novel complex inflammatory bowel disease mouse model: Reproducing human inflammatory bowel disease etiologies in mice.
    PLoS One. 2024;19:e0311310.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.